Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION 
Washington, D.C. 20549
 
 
FORM 8-K
 
CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 16, 2010
 
 
ORAMED PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
 
Nevada
(State or other jurisdiction
of incorporation)
000-50298
(Commission File Number)
98-0376008
(IRS Employer
Identification No.)

Hi-Tech Park 2/5 Givat Ram
PO Box 39098
Jerusalem, Israel 91390
 (Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: 972-2-566-0001
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
 
 
ITEM 7.01
REGULATION FD DISCLOSURE

On June 15, 2010, Oramed Pharmaceuticals Inc. issued a press release announcing that results of two of its clinical trials will be presented by its Chief Scientific Officer Dr. Miriam Kidron, at the forthcoming 70th annual Scientific Sessions of the American Diabetes Association, to be held in Orlando, Florida on June 28, 2010.

A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.

ITEM 9.01
FINANCIAL STATEMENTS AND EXHIBITS.

(d)
Exhibits

Exhibit Number
  
Description
     
99.1
  
Press Release dated June 15, 2010.
 
 
SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
   
ORAMED PHARMACEUTICALS INC. 
  
Dated: June 16, 2010
        
   
By: 
/s/ Nadav Kidron 
  
     
Nadav Kidron 
  
     
President, CEO and Director 
  

 
Exhibit Index

Exhibit Number
  
Description
     
99.1
  
Press Release dated June 15, 2010.